Trevogrumab: Side Effects
Known side effects, contraindications, and interactions
๐TL;DR
- โข5 known side effects documented
- โข5 mild, 0 moderate, 0 severe
- โข3 contraindications listed
Compare side effects across multiple peptides โ
Side Effects Severity Chart
Reported across trevogrumab treatment groups in the COURAGE trial. Muscle spasms are consistent with myostatin pathway blockade and enhanced muscle contractility. Similar to the most common adverse event seen with bimagrumab and other myostatin pathway modulators.
Observed in COURAGE trial participants. Likely primarily attributable to concurrent semaglutide treatment rather than trevogrumab, as nausea is one of the most common GLP-1 agonist side effects.
Reported in COURAGE trial. May be related to semaglutide co-administration, though GI effects have also been observed with other myostatin pathway modulators.
Observed in COURAGE trial participants. Likely primarily attributable to concurrent semaglutide treatment.
Reported in >=5% of participants in COURAGE trial treatment groups.
โContraindications
- โขTrevogrumab has not been approved for any indication. Formal contraindications have not been established. The following are theoretical considerations from clinical trial exclusion criteria.
- โขPregnancy and breastfeeding, as myostatin signaling may play roles in fetal muscle development.
- โขConditions requiring maintained myostatin signaling for physiological balance (theoretical).
โ ๏ธDrug Interactions
- โขGLP-1 receptor agonists (semaglutide) have been studied in combination with trevogrumab in the COURAGE trial. The dual combination was generally well-tolerated with adverse events consistent with individual drug profiles.
- โขGaretosmab (anti-activin A antibody, REGN2477) was studied as a triplet with trevogrumab and semaglutide. The triplet combination showed substantially higher discontinuation rates (28.3%) and had two deaths, raising safety concerns about the three-drug combination.
- โขTheoretical interaction with other myostatin pathway modulators (e.g., bimagrumab, apitegromab, follistatin gene therapy) given overlapping pathway targets.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 15+ community reports
View community protocolsClinical Trial Safety Data#
Trevogrumab's safety profile is primarily characterized by data from the Phase 2 COURAGE trial (999 patients) and the Phase 1 trial in postmenopausal women (82 subjects). The safety data vary substantially between the dual combination (semaglutide + trevogrumab) and the triplet combination (semaglutide + trevogrumab + garetosmab).
Reported Side Effects#
Most Common Adverse Events (COURAGE Trial)#
Adverse events reported in 5% or more of participants across treatment groups:
| Side Effect | Likely Source | Severity |
|---|---|---|
| Muscle spasms | Trevogrumab (myostatin blockade) | Mild |
| Nausea | Semaglutide (GLP-1 agonist) | Mild-Moderate |
| Constipation | Semaglutide | Mild |
| Fatigue | Either/Both | Mild |
| Diarrhea | Either/Both | Mild |
| Headache | Either/Both | Mild |
| Vomiting | Semaglutide | Mild-Moderate |
| GERD | Semaglutide | Mild |
| Upper respiratory infection | Unrelated | Mild |
Safety by Treatment Arm (COURAGE, 26 weeks)#
| Safety Metric | Sema alone | + Trevo 200 mg | + Trevo 400 mg | + Trevo + Gareto |
|---|---|---|---|---|
| Any TEAE | 64.9% | Not reported | Not reported | 77.2% |
| Severe TEAEs | 2.0% | 1.4% | 3.3% | 10.1% |
| Discontinuation | 4-10% | 4-10% | 4-10% | 28.3% |
| Deaths | 0 | 0 | 0 | 2 |
Critical Safety Signal: Triplet Therapy#
The triplet combination (semaglutide + trevogrumab + garetosmab) showed concerning safety signals compared to the dual combinations:
- 28.3% discontinuation rate vs 4-10% in other groups
- 10.1% severe TEAEs vs 1.4-3.3% in dual therapy groups
- Two deaths occurred in the triplet group:
- One due to undetermined cause in a patient with multiple cardiovascular risk factors
- One due to cardiac arrest in a person with history of cardiovascular disease
- Regeneron stated they have not identified a causal association between treatment and these events
Phase 1 Safety (Postmenopausal Women)#
In the Phase 1 trial (PMID 40360471):
- Trevogrumab alone and in combination with garetosmab was generally well-tolerated
- No subjects tested positive for anti-drug antibodies post-treatment
- No dose-limiting toxicities reported
Theoretical Concerns#
Selective vs Broad Pathway Blockade#
Unlike bimagrumab (which blocks multiple TGF-beta superfamily ligands), trevogrumab's selectivity for myostatin reduces certain theoretical risks:
| Concern | Trevogrumab Risk | Bimagrumab Risk |
|---|---|---|
| BMP-9/10 vascular effects | Not expected (no binding) | Theoretical risk |
| Activin A reproductive effects | Not expected (no binding) | Theoretical risk |
| GDF-11 aging pathway effects | Not expected (no binding) | Theoretical risk |
| Myostatin-related muscle effects | Expected (intended) | Expected (part of mechanism) |
However, the limited scope of myostatin-only blockade may also explain why trevogrumab alone preserved only ~50% of lean mass, while the triplet therapy (adding activin A blockade) achieved 80.9% preservation.
Long-Term Myostatin Blockade#
The consequences of chronic myostatin blockade in humans are not fully characterized:
- Animal myostatin knockout models show cardiac hypertrophy at extreme levels
- Whether pharmacological blockade at therapeutic doses carries similar risks is unknown
- Myostatin may have roles in tendon and connective tissue biology
Immunogenicity#
As a fully human antibody generated by VelocImmune technology, trevogrumab has a low expected immunogenicity profile. The Phase 1 trial showed no anti-drug antibody formation.
Overall Safety Assessment#
| Assessment Criterion | Rating | Basis |
|---|---|---|
| Dual therapy tolerability | Favorable | COURAGE 26-week data, low discontinuation |
| Triplet therapy tolerability | Concerning | High discontinuation, severe TEAEs, deaths |
| Severity of common AEs | Mild | Muscle spasms, GI events |
| Immunogenicity | Low | No ADAs in Phase 1 |
| Long-term safety | Unknown | No data beyond 26 weeks |
| Cardiovascular safety | Unknown | Deaths in triplet arm under investigation |
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Trevogrumab
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.